ASX - By Stock
|
MSB |
Re:
Ann: Trading halt
|
|
jb13qz
|
796 |
398K |
5 |
17/12/20 |
17/12/20 |
ASX - By Stock
|
796
|
398K
|
5
|
|
ASX - By Stock
|
MSB |
Re:
Ann: Mesoblast Phase 3 Chronic Heart Failure Results
|
|
jb13qz
|
1.0K |
423K |
3 |
15/12/20 |
15/12/20 |
ASX - By Stock
|
1.0K
|
423K
|
3
|
|
ASX - By Stock
|
MSB |
Re:
Ann: Remestemcel-L FDA Fast Track Designation for COVID-19 ARDS
|
|
jb13qz
|
572 |
255K |
5 |
02/12/20 |
02/12/20 |
ASX - By Stock
|
572
|
255K
|
5
|
|
ASX - By Stock
|
MSB |
Re:
Ann: Novartis and Mesoblast Remestemcel-L Collaboration
|
|
jb13qz
|
811 |
339K |
3 |
23/11/20 |
23/11/20 |
ASX - By Stock
|
811
|
339K
|
3
|
|
ASX - By Stock
|
MSB |
Re:
Ann: Novartis and Mesoblast Remestemcel-L Collaboration
|
|
jb13qz
|
811 |
339K |
2 |
20/11/20 |
20/11/20 |
ASX - By Stock
|
811
|
339K
|
2
|
|
ASX - By Stock
|
MSB |
Re:
Ann: Novartis and Mesoblast Remestemcel-L Collaboration
|
|
jb13qz
|
811 |
339K |
3 |
20/11/20 |
20/11/20 |
ASX - By Stock
|
811
|
339K
|
3
|
|
ASX - By Stock
|
MSB |
Re:
Pfizer announcement
|
|
jb13qz
|
127 |
41K |
25 |
10/11/20 |
10/11/20 |
ASX - By Stock
|
127
|
41K
|
25
|
|
ASX - By Stock
|
MSB |
Re:
Ann: COVID-19 ARDS & GVHD Update, Quarterly Report & Appendix 4C
|
|
jb13qz
|
159 |
62K |
0 |
29/10/20 |
29/10/20 |
ASX - By Stock
|
159
|
62K
|
0
|
|
ASX - By Stock
|
MSB |
Re:
Ann: COVID-19 ARDS & GVHD Update, Quarterly Report & Appendix 4C
|
|
jb13qz
|
159 |
62K |
2 |
29/10/20 |
29/10/20 |
ASX - By Stock
|
159
|
62K
|
2
|
|
ASX - By Stock
|
MSB |
Re:
Ann: Phase 3 Trial in COVID-19 ARDS Surpasses 50% Enrollment
|
|
jb13qz
|
445 |
196K |
11 |
14/10/20 |
14/10/20 |
ASX - By Stock
|
445
|
196K
|
11
|
|
ASX - By Stock
|
MSB |
Re:
Ann: Phase 3 Trial in COVID-19 ARDS Surpasses 50% Enrollment
|
|
jb13qz
|
445 |
196K |
29 |
13/10/20 |
13/10/20 |
ASX - By Stock
|
445
|
196K
|
29
|
|
ASX - By Stock
|
MSB |
Re:
MSB to dispute FDA finding in Type A meeting
|
|
jb13qz
|
1.0K |
509K |
3 |
05/10/20 |
05/10/20 |
ASX - By Stock
|
1.0K
|
509K
|
3
|
|
ASX - By Stock
|
MSB |
Re:
Worst trade of the year
|
|
jb13qz
|
173 |
91K |
8 |
03/10/20 |
03/10/20 |
ASX - By Stock
|
173
|
91K
|
8
|
|
ASX - By Stock
|
MSB |
Re:
What planet are the FDA on
|
|
jb13qz
|
148 |
59K |
7 |
03/10/20 |
03/10/20 |
ASX - By Stock
|
148
|
59K
|
7
|
|
ASX - By Stock
|
MSB |
Re:
Cell Therapy News/Articles
|
|
jb13qz
|
18K |
7.0M |
3 |
03/10/20 |
03/10/20 |
ASX - By Stock
|
18K
|
7.0M
|
3
|
|
ASX - By Stock
|
MSB |
Re:
Over $2buck hit
|
|
jb13qz
|
15 |
6.3K |
1 |
02/10/20 |
02/10/20 |
ASX - By Stock
|
15
|
6.3K
|
1
|
|
ASX - By Stock
|
MSB |
Re:
Over $2buck hit
|
|
jb13qz
|
15 |
6.3K |
3 |
02/10/20 |
02/10/20 |
ASX - By Stock
|
15
|
6.3K
|
3
|
|
World Politics
|
|
Re:
Trump and Melania tested positive for the Wuhan.
|
|
jb13qz
|
50 |
12K |
3 |
02/10/20 |
02/10/20 |
World Politics
|
50
|
12K
|
3
|
|
ASX - By Stock
|
MSB |
Re:
What planet are the FDA on
|
|
jb13qz
|
148 |
59K |
1 |
02/10/20 |
02/10/20 |
ASX - By Stock
|
148
|
59K
|
1
|
|
ASX - By Stock
|
MSB |
Re:
Cell Therapy News/Articles
|
|
jb13qz
|
18K |
7.0M |
3 |
02/10/20 |
02/10/20 |
ASX - By Stock
|
18K
|
7.0M
|
3
|
|
ASX - By Stock
|
MSB |
Re:
Speculative 8-month target - $33.00 MSB for GVHD, COVID ARDS
|
|
jb13qz
|
139 |
96K |
4 |
29/09/20 |
29/09/20 |
ASX - By Stock
|
139
|
96K
|
4
|
|
ASX - By Stock
|
MSB |
Re:
Cell Therapy News/Articles
|
|
jb13qz
|
18K |
7.0M |
2 |
11/09/20 |
11/09/20 |
ASX - By Stock
|
18K
|
7.0M
|
2
|
|
ASX - By Stock
|
MSB |
Re:
Ann: Ethics Approval to Treat COVID-19 Patients in Australia
|
|
jb13qz
|
320 |
131K |
0 |
03/09/20 |
03/09/20 |
ASX - By Stock
|
320
|
131K
|
0
|
|
ASX - By Stock
|
MSB |
Re:
Ann: Ethics Approval to Treat COVID-19 Patients in Australia
|
|
jb13qz
|
320 |
131K |
0 |
03/09/20 |
03/09/20 |
ASX - By Stock
|
320
|
131K
|
0
|
|
ASX - By Stock
|
MSB |
Re:
Ann: Ethics Approval to Treat COVID-19 Patients in Australia
|
|
jb13qz
|
320 |
131K |
2 |
03/09/20 |
03/09/20 |
ASX - By Stock
|
320
|
131K
|
2
|
|
ASX - By Stock
|
MSB |
Re:
Cell Therapy News/Articles
|
|
jb13qz
|
18K |
7.0M |
6 |
02/09/20 |
02/09/20 |
ASX - By Stock
|
18K
|
7.0M
|
6
|
|
ASX - By Stock
|
MSB |
Re:
Cell Therapy News/Articles
|
|
jb13qz
|
18K |
7.0M |
1 |
02/09/20 |
02/09/20 |
ASX - By Stock
|
18K
|
7.0M
|
1
|
|
ASX - By Stock
|
MSB |
Re:
Ann: Ethics Approval to Treat COVID-19 Patients in Australia
|
|
jb13qz
|
320 |
131K |
7 |
02/09/20 |
02/09/20 |
ASX - By Stock
|
320
|
131K
|
7
|
|
ASX - By Stock
|
MSB |
Re:
Ann: Ethics Approval to Treat COVID-19 Patients in Australia
|
|
jb13qz
|
320 |
131K |
6 |
02/09/20 |
02/09/20 |
ASX - By Stock
|
320
|
131K
|
6
|
|
ASX - By Stock
|
MSB |
Re:
Overwhelming efficacy - the stats required
|
|
jb13qz
|
576 |
236K |
2 |
01/09/20 |
01/09/20 |
ASX - By Stock
|
576
|
236K
|
2
|
|
ASX - By Stock
|
MSB |
Re:
Overwhelming efficacy - the stats required
|
|
jb13qz
|
576 |
236K |
7 |
01/09/20 |
01/09/20 |
ASX - By Stock
|
576
|
236K
|
7
|
|
ASX - By Stock
|
MSB |
Re:
Overwhelming efficacy - the stats required
|
|
jb13qz
|
576 |
236K |
6 |
01/09/20 |
01/09/20 |
ASX - By Stock
|
576
|
236K
|
6
|
|
ASX - By Stock
|
MSB |
Re:
Overwhelming efficacy - the stats required
|
|
jb13qz
|
576 |
236K |
11 |
31/08/20 |
31/08/20 |
ASX - By Stock
|
576
|
236K
|
11
|
|
ASX - By Stock
|
MSB |
Re:
Overwhelming efficacy - the stats required
|
|
jb13qz
|
576 |
236K |
3 |
31/08/20 |
31/08/20 |
ASX - By Stock
|
576
|
236K
|
3
|
|
ASX - By Stock
|
MSB |
Re:
Overwhelming efficacy - the stats required
|
|
jb13qz
|
576 |
236K |
1 |
31/08/20 |
31/08/20 |
ASX - By Stock
|
576
|
236K
|
1
|
|
ASX - By Stock
|
MSB |
Re:
Overwhelming efficacy - the stats required
|
|
jb13qz
|
576 |
236K |
7 |
31/08/20 |
31/08/20 |
ASX - By Stock
|
576
|
236K
|
7
|
|
ASX - By Stock
|
MSB |
Re:
Overwhelming efficacy - the stats required
|
|
jb13qz
|
576 |
236K |
2 |
31/08/20 |
31/08/20 |
ASX - By Stock
|
576
|
236K
|
2
|
|
ASX - By Stock
|
MSB |
Re:
Overwhelming efficacy - the stats required
|
|
jb13qz
|
576 |
236K |
3 |
31/08/20 |
31/08/20 |
ASX - By Stock
|
576
|
236K
|
3
|
|
ASX - By Stock
|
MSB |
Re:
Overwhelming efficacy - the stats required
|
|
jb13qz
|
576 |
236K |
7 |
31/08/20 |
31/08/20 |
ASX - By Stock
|
576
|
236K
|
7
|
|
ASX - By Stock
|
MSB |
Re:
Overwhelming efficacy - the stats required
|
|
jb13qz
|
576 |
236K |
1 |
31/08/20 |
31/08/20 |
ASX - By Stock
|
576
|
236K
|
1
|
|
ASX - By Stock
|
MSB |
Re:
Overwhelming efficacy - the stats required
|
|
jb13qz
|
576 |
236K |
1 |
31/08/20 |
31/08/20 |
ASX - By Stock
|
576
|
236K
|
1
|
|
ASX - By Stock
|
MSB |
Re:
Cell Therapy News/Articles
|
|
jb13qz
|
18K |
7.0M |
5 |
31/08/20 |
31/08/20 |
ASX - By Stock
|
18K
|
7.0M
|
5
|
|
ASX - By Stock
|
MSB |
Re:
Overwhelming efficacy - the stats required
|
|
jb13qz
|
576 |
236K |
2 |
28/08/20 |
28/08/20 |
ASX - By Stock
|
576
|
236K
|
2
|
|
ASX - By Stock
|
MSB |
Re:
Overwhelming efficacy - the stats required
|
|
jb13qz
|
576 |
236K |
1 |
28/08/20 |
28/08/20 |
ASX - By Stock
|
576
|
236K
|
1
|
|
ASX - By Stock
|
MSB |
Re:
Overwhelming efficacy - the stats required
|
|
jb13qz
|
576 |
236K |
5 |
27/08/20 |
27/08/20 |
ASX - By Stock
|
576
|
236K
|
5
|
|
ASX - By Stock
|
MSB |
Re:
Overwhelming efficacy - the stats required
|
|
jb13qz
|
576 |
236K |
14 |
26/08/20 |
26/08/20 |
ASX - By Stock
|
576
|
236K
|
14
|
|
ASX - By Stock
|
MSB |
Re:
Overwhelming efficacy - the stats required
|
|
jb13qz
|
576 |
236K |
2 |
25/08/20 |
25/08/20 |
ASX - By Stock
|
576
|
236K
|
2
|
|
ASX - By Stock
|
MSB |
Re:
Overwhelming efficacy - the stats required
|
|
jb13qz
|
576 |
236K |
2 |
25/08/20 |
25/08/20 |
ASX - By Stock
|
576
|
236K
|
2
|
|
ASX - By Stock
|
MSB |
Re:
Overwhelming efficacy - the stats required
|
|
jb13qz
|
576 |
236K |
6 |
25/08/20 |
25/08/20 |
ASX - By Stock
|
576
|
236K
|
6
|
|
ASX - By Stock
|
MSB |
Re:
Cell Therapy News/Articles
|
|
jb13qz
|
18K |
7.0M |
3 |
25/08/20 |
25/08/20 |
ASX - By Stock
|
18K
|
7.0M
|
3
|
|